GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adverum Biotechnologies Inc (STU:AVU0) » Definitions » Cyclically Adjusted PB Ratio

Adverum Biotechnologies (STU:AVU0) Cyclically Adjusted PB Ratio : (As of Jun. 09, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Adverum Biotechnologies Cyclically Adjusted PB Ratio?

Note: If the price history is too short, we do not calculate current Cyclically Adjusted PB Ratio for this stock. All the historical data is shown as the company's primary share's data instead.

Shiller PE for Stocks: The True Measure of Stock Valuation


Adverum Biotechnologies Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Adverum Biotechnologies's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Adverum Biotechnologies Cyclically Adjusted PB Ratio Chart

Adverum Biotechnologies Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 0.11 0.14

Adverum Biotechnologies Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.14 0.30 0.29 0.14 0.27

Competitive Comparison of Adverum Biotechnologies's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Adverum Biotechnologies's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Adverum Biotechnologies's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Adverum Biotechnologies's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Adverum Biotechnologies's Cyclically Adjusted PB Ratio falls into.



Adverum Biotechnologies Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Adverum Biotechnologies's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Adverum Biotechnologies's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=16.534/131.7762*131.7762
=16.534

Current CPI (Mar. 2024) = 131.7762.

Adverum Biotechnologies Quarterly Data

Book Value per Share CPI Adj_Book
201406 -5.847 100.560 -7.662
201409 53.782 100.428 70.570
201412 53.279 99.070 70.868
201503 101.447 99.621 134.191
201506 93.915 100.684 122.917
201509 90.750 100.392 119.121
201512 89.672 99.792 118.412
201603 80.061 100.470 105.007
201606 53.340 101.688 69.123
201609 50.453 101.861 65.270
201612 48.891 101.863 63.249
201703 44.013 102.862 56.385
201706 39.591 103.349 50.481
201709 34.895 104.136 44.157
201712 31.726 104.011 40.195
201803 32.064 105.290 40.130
201806 31.903 106.317 39.543
201809 29.403 106.507 36.379
201812 28.083 105.998 34.913
201903 26.290 107.251 32.302
201906 24.434 108.070 29.794
201909 23.088 108.329 28.085
201912 23.387 108.420 28.425
202003 34.437 108.902 41.670
202006 31.116 108.767 37.698
202009 40.479 109.815 48.574
202012 36.600 109.897 43.887
202103 35.583 111.754 41.958
202106 32.072 114.631 36.869
202109 29.966 115.734 34.120
202112 28.443 117.630 31.864
202203 26.013 121.301 28.259
202206 23.263 125.017 24.521
202209 21.099 125.227 22.203
202212 17.115 125.222 18.011
202303 14.651 127.348 15.160
202306 11.987 128.729 12.271
202309 9.526 129.860 9.667
202312 7.546 129.419 7.683
202403 16.534 131.776 16.534

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Adverum Biotechnologies  (STU:AVU0) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Adverum Biotechnologies Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Adverum Biotechnologies's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Adverum Biotechnologies (STU:AVU0) Business Description

Traded in Other Exchanges
Address
100 Cardinal Way, Redwood CIty, CA, USA, 94063
Adverum Biotechnologies Inc is a U.S.-based clinical-stage gene therapy company. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. The company primarily generates revenue through license, research and collaboration arrangements with its strategic partners. Its lead product candidate is ADVM-022 which is a single, in-office intravitreal (IVT) injection gene therapy designed to deliver long-term durable levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (VEGF) injections. It has one segment developing and commercializing gene therapeutics.

Adverum Biotechnologies (STU:AVU0) Headlines

No Headlines